None of the estimates for this stock were revised in the past 30 days. The Zacks Consensus Estimate, however, has moved up over the same time frame, suggesting that more solid trading could be ahead for Supernus Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Supernus Pharmaceuticals carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked stock in the drugs – generic industry is Akorn, Inc. (AKRX), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment